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A challenge in obstetrics is to distinguish pathological symptoms from those associated with normal changes of preg-
nancy, typiﬁed by the need to differentiate whether gestational pruritus of the skin is an early symptom of intrahepatic
cholestasis of pregnancy (ICP) or due to benign pruritus gravidarum. ICP is characterized by raised serum bile acids
and complicated by spontaneous preterm labor and stillbirth. A biomarker for ICP would be invaluable for early diag-
nosis and treatment and to enable its differentiation from other maternal diseases. Three progesterone sulfate com-
pounds, whose concentrations have not previously been studied, were newly synthesized and assayed in the serum of
three groups of ICP patients and found to be signiﬁcantly higher in ICP at 9-15 weeks of gestation and prior to symp-
tom onset (group 1 cases/samples: ICP n 5 35/80, uncomplicated pregnancy 5 29/100), demonstrating that all three
progesterone sulfates are prognostic for ICP. Concentrations of progesterone sulfates were associated with itch severity
and, in combination with autotaxin, distinguished pregnant women with itch that would subsequently develop ICP
from pruritus gravidarum (group 2: ICP n 5 41, pruritus gravidarum n 5 14). In a third group of ﬁrst-trimester sam-
ples all progesterone sulfates were signiﬁcantly elevated in serum from low-risk asymptomatic women who subsequently
developed ICP (ICP/uncomplicated pregnancy n 5 54/51). Finally, we show mechanistically that progesterone sulfates
mediate itch by evoking a Tgr5-dependent scratch response in mice. Conclusion: Our discovery that sulfated progester-
one metabolites are a prognostic indicator for ICP will help predict onset of ICP and distinguish it from benign pruri-
tus gravidarum, enabling targeted obstetric care to a high-risk population. Delineation of a progesterone sulfate-TGR5
pruritus axis identiﬁes a therapeutic target for itch management in ICP. (HEPATOLOGY 2016;63:1287-1298)
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Amajor challenge for obstetricians is to distin-guish serious disorders associated withincreased maternal and fetal mortality from
low-risk gestational changes. Currently, the presenting
symptoms of many obstetric syndromes are nonspeciﬁc
with few early biomarkers of serious maternal disease.
We aimed to address this problem for intrahepatic
cholestasis of pregnancy (ICP), the commonest liver-
speciﬁc disorder of pregnancy.(1) ICP is complicated
by spontaneous preterm labor, fetal distress, and intra-
uterine death.(1,2) Early recognition of ICP is impor-
tant to enable prompt treatment and appropriate
pregnancy surveillance. The presenting symptom of
ICP is pruritus (skin), and diagnosis is conﬁrmed by
demonstration of raised total serum bile acids. How-
ever, maternal pruritus without hepatic impairment or
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dermatological disorder (i.e., pruritus gravidarum
[PG]) affects up to 25% of pregnant women,(3,4) while
ICP is much less common. It has a variable geographic
prevalence: In the United Kingdom ICP affects 0.7%
of pregnant women but is twice as common in women
of Indian or Pakistani origin,(5) while in Chile it affects
up to 4% of pregnant women.(6)
The etiology of gestational pruritus (both benign and
in ICP) is not established. Several endogenous com-
pounds have been proposed as biochemical mediators
of pruritus in ICP, including lysophosphatidic acid, a
neuronal activator that can act as a pruritogen, the for-
mation of which is catalyzed by the enzyme auto-
taxin.(7,8) These molecules are raised in the serum of
women with ICP after disease onset.(8) The secondary
bile acids deoxycholic acid and lithocholic acid can acti-
vate the G protein-coupled receptor TGR5 on sensory
nerves to stimulate release of itch-selective neuropepti-
des in the spinal cord and evoke a Tgr5-dependent itch
response in mice.(9) These results indicate that bile acids
may induce pruritus but require further evaluation in
ICP as secondary bile acids are not typically raised in
the condition and concentrations of total maternal
serum bile acids do not correlate with pruritus sever-
ity.(10) Although studies of urine samples from ICP
cases implicate progesterone sulfates as pruritogens,(11)
the precise structures of the compounds and their
capacity to cause pruritus remain to be determined.
Sulfated progesterone metabolites contribute to the
etiology of ICP; they are partial agonists of the bile acid
receptor farnesoid X receptor (FXR)(12) and competi-
tively inhibit hepatic bile acid uptake(13) and efﬂux,(14)
resulting in cholestasis and hypercholanemia.(12) Serum
concentrations of progesterone sulfates are elevated in
women with ICP at 35-41 weeks of gestation,(12,15) typi-
cally after diagnosis. We hypothesized that progesterone
sulfates are raised in early pregnancy prior to the onset of
ICP and thus are potential early biomarkers that can dis-
tinguish ICP from benign PG. We also hypothesized
that they signal through TGR5 to mediate pruritus.
This study used three groups of ICP cases and
pregnant controls to establish whether progesterone
sulfates are biomarker candidates for ICP diagnosis
prior to biochemical derangement and to evaluate
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their role and potential mechanism of action as pruri-
togens using in vitro and in vivo approaches. Our
results reveal a key role for the progesterone sulfate-
TGR5 axis in ICP.
Materials and Methods
STUDY APPROVAL
This study conformed to the 1975 Declaration of
Helsinki guidelines; permission was obtained from the
ethics committees of Hammersmith Hospitals NHS
Trust, London (97/5197 and 08/H0707/21), and
King’s College Hospitals NHS Trust, London
(03WH06). Written informed consent was received
from participants prior to inclusion in the study.
Murine studies were approved by the Monash Univer-
sity Animal Ethics Committee.
HUMAN SERUM SAMPLES
Serial blood samples were collected from three pro-
spectively recruited groups of women with ICP, PG,
or controls with uncomplicated pregnancies at intervals
dependent upon gestation and patient attendance.
Sample preparation was as described.(16) Three sepa-
rate patient groups were used, to ensure that results
could be replicated.
Group 1 comprised 64 women: 35 opportunistically
recruited “high-risk” ICP cases with a history of cho-
lestasis in a previous pregnancy and 29 with uncompli-
cated pregnancies. Women with ICP commenced
ursodeoxycholic acid (UDCA) treatment per personal
and practitioner preference following diagnosis (seven
were untreated, six were treated with UDCA, and 22
were recruited untreated and subsequently UDCA-
treated). Group 2 (the pruritus group) comprised 55
women with skin pruritus in pregnancy, 41 of whom
had pregnancies complicated by ICP (23 with previous
ICP) and 14 of whom had normal pregnancies (nine
with previous ICP); of the women who subsequently
developed ICP, 14 provided serum samples prior to
the onset of hypercholanemia (raised bile acids) but
after the onset of pruritus. Women in groups 1 and 2
were recruited while undergoing antenatal care at the
tertiary hospitals of Imperial College London or
through the ICP Support charity. Cases were recruited
between 2007 and 2014 and selected to include all
cases where longitudinal samples were available;
20% of ICP cases were tertiary referrals (of this group
71% were referred from specialists in different UK
regions and 29% were referred from the UK charity
ICP Support).
To evaluate whether progesterone sulfate concen-
trations reduce after delivery, we identiﬁed postnatal
serum samples from a subgroup of 12 ICP cases
(due to the limited number of postnatal samples
collected) and compared the concentration of pro-
gesterone sulfates with the third-trimester serum
sample.
Group 3 comprised 105 asymptomatic women at
11-14 weeks’ gestation, 54 of whom later developed
ICP and 51 of whom subsequently had normal
pregnancies. Women were recruited at aneuploidy
screening at King’s College Hospital, serum sam-
ples were taken, and clinical follow-up by a
research midwife identiﬁed women who developed
ICP; the next sample taken from a woman with a
normal pregnancy was then used as a control
(serum analyses were incomplete due to technical
error resulting in exclusion of three women with
normal pregnancies).
All cases of ICP were conﬁrmed by demonstration
of serum bile acids 10 lmol/L, and some cases also
had raised liver transaminases in association with pru-
ritus and no additional identiﬁable cause for their liver
dysfunction. Exclusion criteria were other causes of
hepatic dysfunction, including preeclampsia; hemoly-
sis, elevated liver enzymes, and low platelets (HELLP)
syndrome; acute fatty liver of pregnancy; primary bili-
ary cirrhosis; active viral hepatitis; any ultrasound
abnormality that may result in biliary obstruction; and
multifetal pregnancy.
BIOPHYSICAL PROFILING OF
PARTICIPANTS
Details of the participants’ relevant previous medi-
cal history, family history, ethnicity, results of inves-
tigations, pregnancy, and delivery were taken
throughout their attendance. Birth weight centile
was calculated according to gestational age and
weight at delivery(17) using GROW software (http://
www.gestation.net/cc/about.htm). At the time of
serum sampling, patients with pruritus used a hori-
zontal visual analogue score(18) (0-100 mm) to quan-
tify in millimeters the worst itch symptoms
experienced over the previous 24 hours. The marked
point was measured, and the distance in millimeters
from 0 (no itch) was converted to an itch score from
0 to 100. The itch analogue score quantiﬁed severity
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of pruritus but did not specify the physical location
and extent of the itch.
Prior to analysis, participants were grouped accord-
ing to retrospective assessment of their diagnosis of
ICP at any point during the pregnancy.
SERUM BILE ACID AND
PROGESTERONE SULFATE
ANALYSIS BY HIGH-
PERFORMANCE LIQUID
CHROMATOGRAPHY-TANDEM
MASS SPECTROMETRY
Internal standards (100 ng of d4-glycholic acid, d4-
glycochenodeoxycholic acid, d4-glycodeoxycholic acid,
d4-glyco-UDCA, d4-glycolithocholic acid, d4-
UDCA, d4-lithocholic acid (all from Qmx Laborato-
ries, Essex, UK), d5-cholic acid (Toronto Research
Chemicals, Toronto, Canada), and d4-taurocholic acid
(TLC PharmaChem, Vaughan, Canada), dissolved in
40 lL methanol [MeOH]) were added to 100 lL of
serum and vortexed. Acetonitrile (800 lL) was added
to precipitate proteins. After vortexing and centrifuga-
tion, the supernatant was dried in a stream of nitrogen
and then ﬁrst taken up in 125 lL MeOH, followed by
125 lL of an aqueous solution containing 40%
MeOH, 0.02% formic acid, and 10 mmol/L ammo-
nium acetate. Before injection 75 lL of the sample was
transferred to new vials and 80 lL of the following
mix was added: three parts of MeOH and one part of
an aqueous solution containing 40% MeOH, 0.02%
formic acid, and 10 mmol/L ammonium acetate.
Ten microliters of this mixture was analyzed on a
high-performance liquid chromatography Alliance
2695 system coupled to a Xevo TQ mass spectrometer
(Waters, Manchester, UK) using a SunFire C18 (4.6
3 100 mm, 3.5 lm) column (Waters) and gradient
elution with 0.01% formic acid and 5 mmol/L ammo-
nium acetate in water along with 0.01% formic acid 1
5 mmol/L ammonium acetate in MeOH as the mobile
phase. Cone voltage was 60 V and collision energy 18
eV for unconjugated bile acids, 60 V and 29-43 eV for
glycine conjugates, and 88 V and 56-65 eV for taurine
conjugates, respectively. Analytes were detected using
selected ion monitoring and quantiﬁed by internal
standard methods. The desolvation temperature was
6508C, and the source temperature was 1508C.
Selected reaction monitoring was used with dwell
times of 100 ms. Analytes were quantiﬁed using deu-
terized internal standards except for progesterone sul-
fates for which d4-glyco-UDCA was used. Results
were calculated as response (area analyte/areainternal std).
Retention times and response curves of bile acids listed
(Supporting Table S1) were evaluated from reference
compounds obtained from Sigma; 5b-pregnan-3b-ol,
20-one,3-sulfate (pregnandiol-3-sulfate), 5a-pregnan-
3a-ol,20-one,3-sulfate (allopregnandiol-3-sulfate), and
5a-pregnan-3b-ol,20-one,3-sulfate (epiallopregnandiol-
3-sulfate) were obtained from Steraloids, USA; 5b-
pregnan-3a,20a-diol-3-sulfate, 5b-pregnan-3a,20a-diol-
disulfate, and 5a-pregnan-3a,20a-diol-disulfate were
from Sai Advantium, India. 5a-Pregnan-3b,20a-diol-
disulfate was tentatively identiﬁed as the remaining iso-
mer from its retention times and mass spectrum. 5b-
Pregnan-3a,20a-diol-disulfate and 5a-pregnan-3a,20a-
diol-disulfate coeluted at all of the conditions tested.
Using this system, we observed less than 10% intra-assay
variability when rerunning the same sample. These
assays were performed in the Department of Molecular
and Clinical Medicine, University of Gothenburg,
Gothenburg, Sweden.
MEASUREMENT OF SERUM
AUTOTAXIN ACTIVITY
Autotaxin activity was measured as described.(7)
Serum was incubated with 1 mmol/L lysophosphati-
dylcholine 14:0, 500 mmol/L NaCl, 5 mmol/L
MgCl2, 100 mmol/L Tris (pH 9.0), and 0.05% Tri-
ton X-100 for 60 minutes at 37oC. Liberated choline
was detected using choline oxidase (2 U/mL), horse-
radish peroxidase (1.6 U/mL), and homovanillic acid,
with emitted ﬂuorescence recorded using a NOVOs-
tar analyzer. Using this system, we observed less than
10% inter-assay and intra-assay variance. The auto-
taxin assay was performed at the Academic Medical
Centre, Amsterdam, The Netherlands.
CYCLIC ADENOSINE
MONOPHOSPHATE
BIOLUMINESCENCE RESONANCE
ENERGY TRANSFER CAMYEL
ASSAY
The bioluminescence resonance energy transfer
CAMYEL (cAMP sensor using YFP-Epac-RLuc)
cyclic adenosine monophosphate (cAMP) sensor
permits quantiﬁcation of intracellular cAMP concen-
trations with high sensitivity and a broad dynamic
range(19) and has been used previously to measure
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TGR5 signaling in cells.(20) HEK293 cells that stably
express the TGR5 receptor were generated using the
FLP-In system (Invitrogen). The characterization of
these cells has been described.(21) HEK293 and
HEK-HA-TGR5 cells (4 3 106 per 10-cm plate)
were transfected with 4 lg of complementary DNA
(cDNA) encoding the CAMYEL sensor. Cells were
transfected using polyethylenimine with a 6:1 polye-
thylenimine:cDNA ratio in 500 lL of 0.15 M NaCl.
The polyethylenimine:cDNA mixture was added to
the cells in the 10-cm plate, and cells were incubated
overnight in 5% CO2 at 378C in Dulbecco’s modiﬁed
Eagle’s medium supplemented with 10% fetal bovine
serum. Cells were washed in phosphate-buffered
saline and incubated in 1 mL of versene for 10
minutes. Cells were suspended in Dulbecco’s modiﬁed
Eagle’s medium and 10% fetal bovine serum, plated
onto poly-D-lysine-treated 96-well plates, and incu-
bated overnight in 5% CO2 at 378C. To test cAMP
production, cells were washed in prewarmed Hank’s
balanced salt solution and then incubated in 80 lL
Hank’s balanced salt solution for 30 minutes at 378C.
Coelenterazine (NanoLight Technology, Pinetop,
AZ; 10 lL of 10 lmol/L in Hank’s balanced salt solu-
tion) was added, and cells were incubated in the dark
for 10 minutes at 378C. Luminescence for RLuc8
(480 nm) and YFP (530 nm) was measured using a
microplate reader (PHERAstar Omega; BMG Lab-
tech, Mornington, Australia). A 2-minute baseline
was established before addition of the agonists. cAMP
production was measured for 10 minutes following
addition of the agonists, forskolin (10 lmol/L), or
vehicle. Baseline and vehicle control values were sub-
tracted, and the bioluminescence resonance energy
transfer signal was normalized as a percentage of the
forskolin response. This assay was performed at Mon-
ash University, Parkville, Australia.
SCRATCHING BEHAVIOR
Scratching behavior was studied in mice (C57BL/6
(wild-type [WT]), Tgr5 knockout [KO], male and
female, 6-10 weeks) as described.(9) The fur at the base
of the neck was shaved, and mice were placed in indi-
vidual cylinders on a glass shelf. Mice were acclimatized
to the experimental room, restraint apparatus, and
investigator for 2-hour periods on 2 successive days
before experiments. After acclimatization, 20 lL of 100
lmol/L 5b-pregnan-3a-20a-diol-sulfate (PM3S) or
vehicle (1% dimethyl sulfoxide) was injected intrader-
mally at the nape of the neck (vehicle WT n 5 4,
PM3S WT n 5 5, PM3S Tgr5-KO n 5 4). Hind
limb scratching to the injection site was video-recorded
for 120 minutes. Two observers unaware of test agents
or genotypes quantiﬁed scratching behavior. One
scratch was deﬁned as lifting the hind limb to the injec-
tion site and then placing the paw on the ﬂoor, regard-
less of the number of strokes. If counts differed by more
than three scratches over a 30-minute period, both
observers reevaluated the record. Results are expressed
as scratching events during 60 minutes of observation.
TRANSACTIVATION ASSAYS
Huh7 cells seeded into 96-well plates were trans-
fected with 10.4 ng plasmid circular DNA (pcDNA)-
retinoid X receptor, 10.4 ng pcDNA-FXRa2/
pcDNA3.1 together with 10.4 ng and 40 ng pGL3-
IBAP-Luc and pcDNA3.1-green ﬂuorescent protein
using Fugene 6 transfection reagent (Promega) at a
3:1 ratio. Twenty-four hours later, cells were washed
and treated with 0 or 50 lM compound 6 0.5 lM
GW4064 (Sigma-Aldrich). After 24 hours, green ﬂu-
orescent protein activity was measured (internal con-
trol for normalization) followed by the addition of
Steadylite plus (PerkinElmer) to determine luciferase
activity, both of which were measured in a PheraStar
FS (BMG) plate reader. Transfection experiments
were performed three times, and the results are shown
as mean values of triplicates and standard deviations.
STATISTICS
For group 1, log transformations of data were
undertaken and results are presented as ratios of the
geometric mean values between groups and over time.
Results were corrected for multiple measures and mul-
tiple markers being analyzed. Interval regression was
used for each assay.
Trend tests were performed by analyzing the
random-effects interval regression on the logged con-
centrations, with interactions between patient groups
and linear effects of time.
For group 2, patient demographic group results
and visual analogue itch scores were compared using
the Mann-Whitney U test, and serial serum concen-
trations of progesterone metabolites using unpaired
Student t test (Prism 6; Graphpad Software Inc.).
Progesterone metabolite concentrations were log-
transformed prior to analysis due to nonnormally dis-
tributed data. Longitudinal comparisons between dis-
ease groups of pruritus scores with biochemical
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markers were performed using Stata software (version
11; StataCorp, College Station, TX). Confounding
based on multiple measures and gestational effects
was accounted for, and subsequent linear and logistic
regression analyses were performed.
For the HEK-HA-TGR5 cAMP assays and murine
scratching assays, results are expressed as mean 6
standard error of the mean. Data were compared statis-
tically using Graphpad Prism 6 for multiple groups
analysis of variance and Tukey-Kramer post hoc test.
P< 0.05 was considered signiﬁcant.
Results
PROGESTERONE SULFATES ARE
PROGNOSTIC INDICATORS OF ICP
To establish whether progesterone sulfates can predict
women at risk of ICP in early pregnancy before symp-
tom onset, a group of ICP cases and uncomplicated
pregnancy controls was used to establish gestational
proﬁles of three sulfated progesterone metabolites
(group 1; Table 1). We obtained the following proges-
terone sulfate standards, which were previously impli-
cated in ICP based on analysis of gas chromatograhic/
mass spectrometric spectra(22,23) and all of which were
synthesized de novo: 5a-pregnan-3a,-20a-diol-3,20-
disulfate (PM2DiS), 5b-pregnan-3a,-20a-diol-3-sulfate
(PM3S), and 5b-pregnan-3a,-20a-diol-3,20-disulfate
(PM3DiS) (Supporting Fig. S1).
A comparison of geometric means across all gesta-
tional weeks for PM2DiS, PM3S, and PM3DiS
revealed, respectively, 4.5-fold, 2.0-fold, and 12.2-
fold signiﬁcant increases in serum concentrations in
untreated ICP cases compared to pregnant controls
(P < 0.001) (Fig. 1). Importantly, concentrations of
PM2DiS, PM3S, and PM3DiS were supraphysiologi-
cally raised compared to normal pregnant controls by
10.6-fold, 1.7-fold, and 24.3-fold, respectively, at
weeks 9-15 (P < 0.05), when 91% of these partici-
pants were asymptomatic, indicating their potential as
predictive biomarkers for ICP. Concentrations of
PM3S in ICP steadily increased at a constant rate
TABLE 1. Clinical and Demographic Characteristics of ICP, PG and Control Cases in Two Groups Used to Evaluate
Sulfated Progesterone Metabolites as Biomarkers
Characteristic
Group 1 Group 2
ICP (n 5 35) Control (n 5 29) P ICP (n 5 41) PG (n 5 14) P
Age (years, 6 SD) 33.4 6 4.6 30.8 6 4.8 0.02 32.7 6 4.3 35.6 6 4.3 0.01
Ethnic group, number (%)
White 22 (63) 27 (93) 0.02 25 (61) 11 (79) NS
Black 4 (11) 0 NS 4 (10) 0 NS
Asian 8 (23) 1 (3) NS 9 (22) 1 (7) NS
Other 1 (3) 1 (3) NS 3 (7) 2 (14) NS
Previous pregnancies 24 weeks, number (%)
0 0 26 (90) <0.01 11 (27) 2 (14) NS
1 20 (57) 1 (3) <0.01 18 (44) 9 (64) NS
2 15 (43) 1 (3) <0.01 11 (27) 2 (14) NS
Unknown 0 1 (3) NS 1 (2) 1 (7) NS
Gestational age at diagnosis (weeks 6 SD) 2911 6 613 n/a 3010 6 712 n/a
Severity of ICP, number (%)
Total bile acids 5 10-39.9 lmol/L 13 (37) n/a 16 (39) n/a
Total bile acids 40 lmol/L 22 (63) n/a 25 (61) n/a
Mean serum ALT, IU/L 6 SD 88.3 6 131.2 n/a 145.3 6 197.2 29.4 6 30.6
Onset of labor, number (%)
Spontaneous 5 (14) 16 (55) <0.01 7 (17) 4 (29) NS
Induced 14 (40) 8 (28) NS 24 (59) 3 (21) 0.02
Prelabor cesarean section 13 (37) 2 (7) 0.02 8 (20) 6 (43) NS
Unknown 3 (9) 3 (10) NS 2 (5) 1 (7) NS
Gestational age at delivery (weeks 6 SD) 3710 6 114 3916 6 112 <0.01 3710 6 113 3812 6 012 <0.01
Preterm delivery <37/40, number (%) 12 (34) 0 <0.01 14 (34) 2 (14) NS
Birth weight, kg 6 SD 3.1 6 0.4 3.5 6 0.4 <0.01 3.1 6 0.4 3.1 6 0.6 NS
Birth weight centile, number 6 SD 67 6 28 49 6 32 0.01 72 6 25 47 6 35 0.01
Mean serum ALT values based on levels detected in the ﬁrst sample obtained from each ICP case. P value shown where a comparison
resulted in statistical signiﬁcance. Values are given as means, unless otherwise stated.
Abbreviations: ALT, alanine transaminase; n/a, not applicable; NS, not signiﬁcant.
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from 9 to 41 weeks, whereas concentrations of
PM3DiS and PM2DiS increased steeply from 24 to
41 weeks for the ICP group compared to controls (P
< 0.05) (Fig. 1).
UDCA treatment improves maternal pruritus and
biochemical derangements in ICP. UDCA signiﬁ-
cantly reduced PM2DiS and PM3DiS concentra-
tions relative to untreated ICP women throughout
the last trimester of pregnancy (P < 0.05). A trend
analysis showed a signiﬁcant change in the trend of
PM3DiS with UDCA treatment in the third trimes-
ter of ICP compared to the untreated ICP group
(P< 0.05), becoming similar to the pregnant control
group trend (Fig. 1).
PROGESTERONE SULFATE
CONCENTRATIONS RAPIDLY
RESOLVE IN ICP SERUM
FOLLOWING PARTURITION
To establish whether progesterone sulfate concen-
trations persist following parturition in ICP, concen-
trations of progesterone metabolites in the last
sample in ICP cases prior to parturition and postnatal
samples collected thereafter were assayed in a sub-
group of patients. Concentrations of PM2DiS,
PM3S, and PM3DiS decreased rapidly following
birth and normalized to almost undetectable levels as
early as 12 days postpartum (Table 2).
PROGESTERONE SULFATES ARE
ASSOCIATED WITH SEVERITY OF
ITCH IN ICP AND CAN PREDICT
ITS SUBSEQUENT ONSET
To assess the involvement of progesterone sulfates
in pruritus, we investigated the relationship between
pruritus severity and serum concentrations of proges-
terone metabolites in women with pregnancy-
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FIG. 1. Gestational serum proﬁles of PM2DiS, PM3S, and
PM3DiS in group 1. Panels A, B, and C show the mean con-
centrations of PM2DiS, PM3S, and PM3DiS, respectively, for
serum samples obtained at different gestational time points from
women with uncomplicated pregnancies (control, closed squares),
untreated ICP (closed circles), and UDCA-treated ICP (closed
triangles). Error bars represent 6 standard error of the mean. P
values for gestational week category comparison of untreated ICP
versus controls were determined by Student t test.
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TABLE 2. Maternal Concentrations of Progesterone Sulfates
in the Last Serum Sample Prior to Parturition and in
Subsequent Postnatal Serum Samples in ICP
Case
Gestational
Day/Postnatal Day
PM3S
(lmol/L)
PM3DiS
(lmol/L)
PM2DiS
(lmol/L)
1 GD 266 8.03 0.62 1.48
PN16 2.24 0.09 0.49
2 GD 241 2.75 1.28 1.27
PN166 0.00 0.00 0.00
3 GD 256 12.44 1.88 3.89
PN134 0.03 0.01 0.00
4 GD 255 7.22 2.19 3.30
PN112 0.04 0.03 0.09
5 GD 232 21.07 6.71 3.31
PN121 0.00 0.00 0.00
6 GD 269 2.28 0.52 1.25
PN140 0.00 0.00 0.00
7 GD 237 47.36 11.81 1.81
PN11 19.99 9.45 0.94
PN142 0.00 0.00 0.00
8 GD 261 9.85 4.76 5.94
PN140 0.02 0.00 0.00
9 GD 248 11.10 14.41 8.97
PN142 0.02 0.00 0.00
10 GD 252 20.04 5.31 4.90
PN113 3.74 3.44 1.72
11 GD 268 23.72 3.88 4.28
PN156 0.06 0.00 0.07
12 GD 255 15.64 5.60 6.04
PN11 9.29 5.15 6.00
Abbreviations: GD, gestational day; PN, postnatal.
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associated pruritus (Table 1). Serum PM2DiS, PM3S,
and PM3DiS concentrations all differentiated women
with ICP from PG (P < 0.05) (Table 3). Serum con-
centrations of PM3S (odds ratio [OR] 5 6.1, 95%
conﬁdence interval [CI] 0.6-11.5, P < 0.05) and auto-
taxin activity (OR 5 1.4, 95% CI 0.3-2.4, P < 0.05)
were signiﬁcantly associated with itch severity in ICP.
To determine whether progesterone sulfates could
predict subsequent ICP, logistic regression was per-
formed on PM2DiS, PM3S, and PM3DiS concentra-
tions and autotaxin activity, using the ﬁrst serum
sample from women at presentation with pruritus and
normal serum biochemistry (Table 4). PM2DiS and
PM3DiS differentiated between the women who
would subsequently develop ICP (P < 0.05, OR 5
2.8, 95% CI 1.5-5.2, and OR 5 2.5, 95% CI 1.2-5.4,
respectively).
To reﬁne a prediction algorithm, we evaluated
whether a combination of markers could more reliably
predict disease. PM2DiS, PM3DiS, and autotaxin in
combination resulted in an improved area under the
receiver operating characteristic (ROC) curve of 0.91
(95% CI 0.80-1.00) in contrast to autotaxin (0.73,
95% CI 0.52-0.94), PM2DiS (0.72, 95% CI 0.52-
0.92), or PM3DiS (0.74, 95% CI 0.55-0.94) alone
(Fig. 2A). Plotting this combination as a predictive
score for the ﬁrst serum sample from women present-
ing with PG enabled clear differentiation between
those who would subsequently develop ICP and those
who continue to have benign PG (Fig. 2B).
PROGESTERONE SULFATES ARE
SUPRAPHYSIOLOGICALLY RAISED
IN EARLY GESTATION IN LOW-
RISK ICP CASES
We evaluated this predictive algorithm in a third
group of asymptomatic pregnant women who gave
serum samples at 11-14 gestational weeks for a study
of serum biomarkers to predict adverse pregnancy out-
come (Table 5). Fifty-four women from this group
developed ICP in later pregnancy, and their progester-
one sulfate concentrations were compared to those of
51 women with uncomplicated pregnancies. PM2DiS,
PM3S, and PM3DiS concentrations were signiﬁcantly
raised in women with subsequent ICP (Table 5).
Autotaxin did not predict ICP at this early gestation
(area under the curve 5 0.55, 95% CI 0.43-0.66),
while PM3DiS and PM2DiS in combination showed
some predictive ability (area under the curve 5 0.68,
95% CI 0.58-0.78) (Supporting Fig. S2).
PROGESTERONE SULFATES
SIGNAL THROUGH TGR5 TO
MEDIATE ITCH
Activation of the G protein-coupled receptor Tgr5
elicits an itch response in mice.(9) We therefore
hypothesized that progesterone metabolites associated
with itch in ICP can activate TGR5 in vitro. HEK
cells stably transfected with TGR5 or empty vector
control cells were transfected with the CAMYEL
cAMP sensor and treated with the cAMP inducer for-
skolin or increasing concentrations of PM2DiS,
PM3S, and PM3DiS. In HEK-TGR5 cells, PM3S
elicited a cAMP response at concentrations of 1
TABLE 3. Associations Between Biochemical Markers and Pruritus Scores and Their Ability to Differentiate ICP From PG
Biomarker
Association With Pruritus
ICP PG Ability to Identify ICP
Change in VAS (95% CI) P Change in VAS (95% CI) P OR (95% CI) P
PM3S 6.1 (0.6-11.5) 0.03 0.9 (24.6–6.3) NS 1.7 (1.1-2.4) 0.01
PM3DiS 2.2 (21.6–6) NS 22.5 (26.2–1.2) NS 2.1 (1.4-3.4) <0.01
PM2DiS 20.3 (25.3–4.6) NS 28.0 (214.9–1.2) 0.03 1.7 (1.2-2.5) 0.01
Autotaxin 1.4 (0.3-2.4) 0.01 2.0 (20.1–4.1) NS 2.3 (2.1-2.6) <0.01
Linear regression results showing the effect of doubling biochemical markers and change in visual analogue score for ICP and PG and
ORs for developing ICP. P value shown where a comparison resulted in statistical signiﬁcance.
Abbreviations: NS, not signiﬁcant; VAS, visual analogue score.
TABLE 4. Autotaxin, PM2DiS, and PM3DiS All Have the
Ability to Predict ICP When Measured at the Time of Onset
of Gestational Pruritus
ICP Marker
OR of Future
ICP (95% CI) P
Area Under
ROC Curve
PM3S 1.70 (0.97-3.01) 0.07 0.45 (0.23-0.68)
PM3DiS 2.77 (1.48-5.19) <0.01 0.74 (0.55-0.94)
PM2DiS 2.54 (1.18-5.44) 0.02 0.72 (0.52-0.92)
Autotaxin 2.22 (0.99-4.86) 0.07 0.73 (0.52-0.94)
Abbreviation: ROC, receiver operating characteristic.
ABU-HAYYEH, OVADIA, ET AL. HEPATOLOGY, April 2016
1294
lmol/L, whereas there was no cAMP response in con-
trol cells. PM3S stimulated a concentration-dependent
formation of cAMP with a 50% effective concentration
of 5.5 lmol/L (Fig. 3A; and Supporting Fig. S3).
Notably, these PM3S concentrations were demon-
strated from 20 weeks’ gestation in women with ICP
(Fig. 1) and signiﬁcantly associated with pruritus
severity (Table 3). In contrast, PM2DiS and PM3DiS
stimulated cAMP formation at extremely high concen-
trations. The temporal proﬁle for the 1 lmol/L
PM3S-mediated cAMP response was consistent with
the rapid actions of an activated G protein-coupled
receptor (Fig. 3B). We also excluded FXR as a possible
mediator of the progesterone sulfate signal as all three
progesterone sulfates were unable to either transacti-
vate FXR or inhibit GW4064-mediated FXR transac-
tivity in an FXR-reporter assay system (Supporting
Fig. S4).
Because PM3S activates TGR5 in HEK-TGR5
cells, we examined whether it could evoke Tgr5-
mediated scratching in mice. PM3S or vehicle (con-
trol) was intradermally injected into the nape of the
neck of WT and Tgr5-KO mice, and scratching
behavior was measured for 60 minutes. In WT mice,
PM3S stimulated a robust scratching response in the
ﬁrst 30 minutes, which was 16-fold higher than that
evoked by vehicle (P < 0.05) (Fig. 3C) and signiﬁ-
cantly blunted by three-fold in Tgr5-KO mice com-
pared to WT mice (P < 0.05) (Fig. 3C). PM3S
continued to stimulate scratching in WT mice from 30
to 60 minutes, whereas the response in Tgr5-KO mice
was attenuated after 30 minutes. Cumulatively over the
whole hour, there was a 21-fold increase in observed
scratches in the PM3S-challenged WT mice
(P < 0.05), which was signiﬁcantly abrogated in the
Tgr5-KO mice (P < 0.05).
Discussion
Our results show that the sulfated progesterone
metabolites PM2DiS, PM3S, and PM3DiS are prog-
nostic for ICP as their concentrations are elevated dur-
ing early gestation when patients are asymptomatic.
Furthermore, UDCA treatment reduces the ICP-
associated elevation of disulfated progesterone
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FIG. 2. Progesterone sulfates and autotaxin can predict subsequent onset of ICP in pregnant women with pruritus. The receiver oper-
ating curves (A) improved toward an optimal area under the curve of 1.0 when biomarkers were evaluated in combination: PM2DiS
1 PM3DiS (complete line), autotaxin (dashed line), and PM2DiS 1 PM3DiS 1 autotaxin (dotted and dashed line). (B) A com-
bined predictive score (PM2DiS 1 PM3DiS 1 autotaxin) of greater than 0.25 for individual samples plotted against the gestational
day of sampling reliably predicted all ICP cases. Women who developed ICP (n 5 14, closed circles) and PG (n 5 14, open trian-
gles) were reliably distinguished by this score; dashed line represents demarcation between the two groups. Abbreviation: AUC, area
under the curve.
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metabolites. Interestingly, concentrations of progester-
one sulfates decrease rapidly following birth, consistent
with clinical reports of rapid resolution of pruritus in
ICP.(24) PM3S concentrations were associated with
the pruritus of ICP, while all three progesterone sul-
fates were able to differentiate between women with
pruritus in pregnancy secondary to ICP and those with
benign PG. Combining PM2DiS, PM3DiS, and
autotaxin activity enabled prediction of women who
would subsequently develop ICP when they ﬁrst
started itching in pregnancy, prior to elevation in bile
acids. Furthermore, concentrations of PM3S consist-
ent with ICP were capable of mediating cAMP release
in a TGR5-dependent manner and resulted in a
scratch response that was reduced in Tgr5-KO mice.
This study has shown that PM3S is a likely prurito-
gen in ICP as concentrations consistent with ICP can
activate TGR5 and mediate a Tgr5-dependent itch.
Although this result is based on a mouse model, Keitel
et al. have also shown that progesterone sulfates can
modulate the activity of TGR5 in other human tis-
sues.(25) We demonstrated that autotaxin and progester-
one sulfates are associated with pruritus in ICP and PG,
and it is likely that autotaxin-mediated elevations in
lysophosphatidic acid cause itch through a distinct
mechanism from that of progesterone sulfate-induced
pruritus.
The demonstration that PM2DiS, PM3S, and
PM3DiS are signiﬁcantly raised in maternal serum
prior to disease onset indicates that women with ICP
are likely to have an underlying abnormality in phase 2
metabolism (conjugation) of progesterone or phase 3
(biliary excretion) of progesterone sulfates.(23) As the
progesterone sulfates that are supraphysiologically
raised in ICP are agonists of the bile acid receptor
TGR5, it is possible that they impact additional down-
stream gestational metabolic pathways mediated by
this receptor.(26) These results have the potential to
provide insights into strategies to treat other cholestatic
disorders complicated by itch, e.g., primary biliary scle-
rosis, primary sclerosing cholangitis, and drug-induced
liver injury. They are likely to also have a global impact
as ICP is commoner in women of South Asian and
South American origin.(5,6)
At present there are no biomarkers for ICP in clini-
cal use. The potential use of the predictive score to
TABLE 5. Maternal Characteristics of Pregnancies Assessed in a Group of Low-Risk Women Taken in the First Trimester of
Pregnancy and Their Pregnancy Outcomes, With Levels of Serum Sulfated Progesterone Metabolites in These
First-Trimester Samples
Characteristic/Marker
Group 3
ICP (n 5 54) Control (n 5 51) P
Age, years 6 SD 32 6 5.4 31 6 5.2 NS
Ethnic group, number (%)
White 42 (78) 35 (69) NS
Black 6 (11) 11 (22) NS
Asian 5 (9) 3 (6) NS
Other 1 (2) 2 (4) NS
Previous pregnancies 24 weeks, number (%)
0 28 (52) 26 (51) NS
1 22 (41) 15 (29) NS
2 4 (7) 10 (20) NS
Onset of labor, number (%)
Spontaneous 12 (22) 46 (90) <0.01
Induced 34 (63) 3 (6) <0.01
Prelabor cesarean section 8 (15) 2 (4) NS
Gestational age at delivery, weeks 6 SD 3813 6 111 4011 6 111 <0.01
Preterm delivery <37/40, number (%) 2 (4) 0 NS
Birth weight, kg 6 SD 3.3 6 0.5 3.4 6 0.3 NS
Birth weight centile, number 6 SD 60 6 30 42 6 23 <0.01
Stillbirth, number (%) 0 0
Progesterone metabolite, lmol/L mean 6 SEM
PM3S 1.4 6 0.1 1.1 6 0.1 0.02
PM3DiS 0.3 6 0 0.2 6 0 <0.01
PM2DiS 2.8 6 0.3 1.9 6 0.2 <0.01
Total bile acids, lmol/L mean 6 SEM 3.9 6 0.4 4 6 0.5 NS
Autotaxin activity, nmol/ml/min 6 SEM 12.9 6 1.2 11.6 6 1.1 NS
P value shown where a comparison resulted in statistical signiﬁcance. Values given as means, unless otherwise stated.
Abbreviations: NS, not signiﬁcant; SD, standard deviation; SEM, standard error of mean.
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establish whether pregnant women with pruritus will
develop ICP is enticing and should be evaluated in
future prospective, well-powered studies. This is
important as the patient groups in the current study
were all managed in a single specialist center and this
may have introduced population bias. If the results are
conﬁrmed in different populations, a feasible exten-
sion to this study would be to assay concentrations of
urinary progesterone sulfates (Glantz et al.(11)) to
identify a predictive score that can be used in early
pregnancy to establish whether a woman with pruritus
will develop this high-risk disease. This could have
wider clinical application with the development of
high-throughput urinary assays for progesterone sul-
fates or similar laboratory tests for serum levels of pro-
gesterone sulfates and autotaxin. This will enable
obstetricians to refer women for hospital care in a
high-risk setting or alternatively to reassure them that
their pruritus is unlikely to have pathological
consequences.
In conclusion, this study describes the mechanism
of action of pruritogens that are prognostic for ICP,
which has the potential to enable obstetricians to
diagnose ICP, a common metabolic disorder of preg-
nancy, prior to onset of symptoms or biochemical
derangements.
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FIG. 3. Progesterone metabolites can activate TGR5 and elicit a Tgr5-mediated itch response in mice. cAMP formation was moni-
tored over time in HEK293 cells expressing TGR5 or control cells that were treated with 10 lmol/L of forskolin or increasing con-
centrations of PM3S, PM3DiS, or PM2DiS. Data are presented as a dose response for all three compounds in both cell types (A) or
time course for PM3S in TGR5-expressing cells (B). Values represent mean 6 standard deviation of n 5 3. (C) Wild-type or Tgr5-
KO mice were intradermally injected with vehicle or 20 lL of 100 lmol/L PM3S, and scratching events were counted for the indi-
cated time periods. Values represent mean 6 standard error of the mean of n  4. *P < 0.05 for vehicle versus PM3S-administered
mice scratch comparison; #P < 0.05 for PM3S WT versus PM3S Tgr5-KO scratch comparison as determined by one-way analysis of
variance. Abbreviation: BRET, bioluminescence resonance energy transfer.
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